

Daftar Pustaka

1. WHO. *Chronic Suppurative Otitis Media, Burden of Illness and Management Options*. (Acuin J, ed.). Geneva: WHO; 2004.
2. Darmawan AB, Anjarwati DU. Perbedaan sensitivitas tetes telinga antibiotik terhadap *Pseudomonas aeruginosa* pada otitis media supuratif kronik. 2012;42(2).
3. Utami TF, Sudarman K, Udji B, Rianto D, Christanto A. Rinitis Alergi sebagai Faktor Risiko Otitis Media Supuratif Kronis. 2010;179.
4. Helmi. *Otitis Media Supuratif Kronis Pengetahuan Dasar Terapi Medik Mastoidotomi Timpanoplasti*. Jakarta: Balai Penerbit FKUI; 2005.
5. *Survey Kesehatan Indera Penglihatan Dan Pendengaran Pada 7 Propinsi Di Indonesia Tahun 1994-1996.*; 1997.
6. Sandeep S. How Safe is Safe Ear?: A Hospital Based Study. *Int J Sci study*. 2014;2(2):3-6.
7. Maniu A, Harabagiu O, Schrepler MP, Cătană A, Fănuță B, Mogoantă CA. Molecular biology of cholesteatoma. *Rom J Morphol Embryol*. 2014;55(1):7-13.
8. Likus W, Siemianowicz K, Markowski J, et al. Bacterial infections and osteoclastogenesis regulators in men and women with cholesteatoma. *Arch Immunol Ther Exp (Warsz)*. 2016;64(3):241-247.
9. Mayer TA, Strunk CL, Lampert PR. Cholesteatoma. In: *Head and Neck Surgery Otolaryngology*. ; 2014:2433-2445.
10. Kuo CL, Shiao AS, Yung M, et al. Updates and knowledge gaps in cholesteatoma research. *Biomed Res Int*. 2015:1-18.
11. Hamed MA, Nakata S, Sayed RH, et al. Pathogenesis and bone resorption in acquired cholesteatoma: Current knowledge and future prospectives. *Clin Exp Otorhinolaryngol*. 2016;9(4):298-308.
12. Kanemaru SI, Kikkawa Y, Omori K, Ito J. Bone destructive mechanisms of cholesteatoma. *Laryngoscope*. 2010;120(3):68.
13. Jung JY, Chole RA. Bone resorption in chronic otitis media: The role of the osteoclast. *Orl*. 2002;64(2):95-107.
14. Jeong J-H, Park C-W, Tae K, et al. Expression of RANKL and OPG in

- middle ear cholesteatoma tissue. *Laryngoscope*. 2006;116(7):1180-1184.
15. Badalà F, Nouri-mahdavi K, Raof DA. Functions of RANKL/RANK/OPG in bone modeling and remodeling. *Arch Biochem Biophys*. 2008;144(5):724-732.
 16. Soysa NS, Alles N, Aoki K, Ohya K. Osteoclast formation and differentiation: An overview. *J Med Dent Sci*. 2012;59(3):65-74.
 17. McGrath EE. OPG/RANKL/RANK pathway as a therapeutic target in cancer. *J Thorac Oncol*. 2011;6(9):1468-1473.
 18. Silva, Branco. RANK/RANKL/OPG literature review. *Acta Rheumatol Port*. 2011;(36):209-218.
 19. Kuczkowski J, Sakowicz-Burkiewicz M, Izycka-Świeszewska E. Expression of the receptor activator for nuclear factor- κ B ligand and osteoprotegerin in chronic otitis media. *Am J Otolaryngol*. 2010;31(6):404-409.
 20. Byun JY, Cha IC, Yeo GS, Kim WS, Cho SJ. Ekspresion of receptor activator of NF- κ B ligand and osteoprotegerin in cholesteatoma. *Korean J Audiol*. 2005;48:955-960.
 21. Chen A-P, Wang B, Zhong F, et al. Expression levels of receptor activator of nuclear factor- κ B ligand and osteoprotegerin are associated with middle ear cholesteatoma risk. *Acta Otolaryngol*. 2015;135(7):655-666.
 22. XIA Ming D, Zhang H, Liu Fang Y, Anting X. Expression and significance of nuclear factor-kappa B ligand and correlation factor in the tissue of otitis media with cholesteatoma. *J Clin Otorhinolaryngol head neck Surg*. 2007;(07):1-5.
 23. Koizumi H, Suzuki H, Ikezaki S, Ohbuchi T, Hashida K, Sakai A. Osteoclasts are not activated in middle ear cholesteatoma. *J Bone Miner Metab*. 2016;34(2):193-200.
 24. Koizumi H, Suzuki H, Kawaguchi R, et al. Presence of osteoclasts in middle ear cholesteatoma: a study of undecalcified bone sections. *Acta Otolaryngol*. 2016:1-3.
 25. Muftah S, Mackenzie I, Faragher B, Brabin B. Prevalence of chronic suppurative otitis media (CSOM) and associated hearing impairment

- among school-aged children in Yemen. *Oman Med J*. 2015;30(5):358-365.
26. Article O, Rehman MUR, Hussain G. Frequency of complications in chronic suppurative otitis media. *J Saidu Med Collage*. 2013;3(2):4-6.
27. Sharma N, Ashok A. Complications of chronic suppurative otitis media and their Management: A single institution 12 years experience. *Indian J Otolaryngol Head Neck Surg*. 2015:1-8.
28. Ahmed Z, Khan TZ, Rahim DU. Otogenic complications of otitis media: experience at tertiary care hospital Received. *Pak J Surg*. 2016;32(1):49-53.
29. Arts A, Adams M. Intratemporal and intracranial complication of otitis media. In: Johnson J, Rosen C, eds. *Bailey's Head and Neck Surgery Otolaryngology*. Lippincot William & Wilkins; 2014:2399-2409.
30. Chang P, Kim S. Cholesteatoma - Diagnosing the unsafe ear. *Aust Fam Physician*. 2008;37(8):631-640.
31. Kuo C. Etiopathogenesis of Acquired Cholesteatoma: Prominent Theories and Recent Advances in Biomolecular Research. *Laryngoscope*. 2014:1-7.
32. Jackler RK, Maria PLS, Varsak YK, Nguyen A, Blevins NH. A new theory on the pathogenesis of acquired cholesteatoma: mucosal traction. *Laryngoscope*. 2015;125(August):1-14.
33. Mostafa BE, El-monayeri MSE, Elfiky L, Mohammed MA, Sarwat AR. Cytokeratin 16 Expression Does Not Indicate Cholesteatoma Aggressiveness. *J Hear Sci*. 2012;(02):50-56.
34. Fukudome S, Chuan W, Jizhen L, et al. Regulation of the Angiogenesis of Acquired Middle Ear Cholesteatomas by Inhibitor of DNA Binding Transcription Factor. *JAMA Otolaryngol Head Neck Surg*. 2013;139(3):273-278.
35. Ney JT, Fehm T, Juhasz-Boess I, Solomayer EF. RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis. *Geburtshilfe Frauenheilkd*. 2012;72(5):385-391.
36. Kini U, Nandeesh BN. Physiology of Bone Formation, Remodeling, and Metabolism. In: Fogelman, ed. *Radionuclide and Hybrid Bone Imaging*. Bangalore: Springer-Verlag Berlin Heidelberg; 2012:29-59.

37. Clarke B. Normal bone anatomy and physiology. *Clin J Am Soc Nephrol.* 2008;3:131-139.
38. Rucci N. Molecular biology of bone remodelling. *Clin Cases Miner Bone Metab.* 2008;5(1):49-56.
39. Williams GR. Actions of thyroid hormones in bone. *Polish J Endocrinol.* 2009;60(5):380-388.
40. Bandeira F, Lazaretti-castro M, Bilezikian JP. Hormones and bone. *Arq Bras Endocrinol Metab.* 2010;54(2):2-3.
41. Wang T, Lin C, Lin C, et al. Increased acquired cholesteatoma risk in patients with osteoporosis: A retrospective cohort study. *PLoS One.* 2015;(7):1-10.
42. Shaik Y, Anogianaki A, Katsano G., et al. Role of cytokines in the pathogenesis of bone resorption. *J Orthop.* 2009;1:25-28.
43. Jin BJ, Min HJ, Jeong JH, Park CW, Lee SH. Expression of EGFR and microvessel density in middle ear cholesteatoma. *Clin Exp Otorhinolaryngol.* 2011;4(2):67-71.
44. Celebi O, Paksoy M, Aydin S, Sahn A, Tasdemir O, Gul EA. Myeloperoxidase activity in the pathogenesis of cholesteatoma. *Indian J Otolaryngol Head Neck Surg.* 2010;62(March):32-35.
45. Nguyen KH, Suzuki H, Ohbuchi T, et al. Possible participation of acidic pH in bone resorption in middle ear cholesteatoma. *Laryngoscope.* 2014;124(1):245-250.
46. Sinha AK, Sharma AK, Ahmad E, Kumar G. Bone resorption in chronic otitis media. *Vertigo.* 2014;5(6):10-90.
47. Aberg B, Edström S, Bagger-Sjöbäck D, Kindblom LG. Morphologic development of experimental cholesteatoma. *Arch Otolaryngol Head Neck Surg.* 1993;119(3):272-275.
48. Bage Ö, Tuz M, Aynali G, Cilickaya M. Is there a systemic inflammatory effect of cholesteatoma? *Int Arch Otorhinolaryngol.* 2017;21(1):42-45.
49. Sigl V, Penninger JM. RANKL/RANK - From bone physiology to breast cancer. *Cytokine Growth Factor Rev.* 2014;25(2):205-214.
50. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK

signaling in osteoclastogenesis and bone disease. *Trends Mol Med.* 2006;12(1):17-25.

51. Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. *Front Immunol.* 2014;5:1-11.
52. Schramek D, Penninger JM. The Many Roles of RANKL-RANK Signaling in Bone , Breast and Cancer. *Int bone Miner Soc.* 2011;8(5):237-256.
53. Kohli SS, Kohli VS. Role of RANKL – RANK / osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. *indian J Endocrinol Metab.* 2011;15(3):175-181.
54. Kelesidis T, Currier JS, Yang OO, Brown TT. Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. *AIDS Rev.* 2014;16(3):123-133.
55. Wasilewska A. Serum Osteoprotegerin (OPG) and Receptor Activator of Nuclear Factor κ B (RANKL) in Healthy Children and Adolescents. *J Pediatr Endocrinol Metab.* 2009;1104(22):1099-1104.
56. Roodman GD. Role of cytokines in the regulation of bone resorption. *Calcif Tissue Int.* 1993;53:S94-8.
57. Santini D, Schiavon G, Vincenzi B, et al. Receptor activator of NF- κ B (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. *PLoS One.* 2011;6(4).
58. Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. *Rheumatology.* 2006;45(9):1068-1076.
59. Azim HA. Bone metastasis in breast cancer : The story of RANKL-Ligand. *J Egypt Natl Canc Inst.* 2012;24(3):107-114.
60. Ibrahim T, Ricci M, Scarpi E, et al. RANKL : A promising circulating marker for bone metastasis response. *Oncol Lett.* 2016;12:2970-2975.
61. Lipton A, Jun S. RANKL inhibition in the treatment of bone metastases. *Curr Opin Support Palliat Care.* 2008;2:197-203.
62. Florencio-Silva R, Sasso GRDS, Sasso-Cerri E, Simões MJ, Cerri PS. Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. *Biomed Res Int.* 2015;2015:1-17.

63. Yoneda T, Tanaka S, Hata K. Role of RANKL / RANK in primary and secondary breast cancer. *World J Orthop.* 2013;4(4):178-185.
64. Azim H, Jr HAA. Targeting RANKL in breast cancer : bone metastasis and beyond. *Expert Rev Anti cancer Ther.* 2013;2:195-202.
65. Miyasato M, Takeno S, Hirakawa K, Fukushima N. Elevated RANKL expression is associated with increased epithelial proliferation and submucosal inflammation in human middle ear cholesteatoma. *Otol Jpn.* 2011;21(5):784-790.
66. Miyasato M, Takeno S, Hirakawa K. Expression of RANKL and proliferation abilities of cultured human middle ear cholesteatoma epithelial cells. *Hiroshima J Med Sci.* 2013;62(1):1-6.
67. Dahiya N, Khadka A, Sharma AK, Gupta AK, Singh N, Brashier DBS. Denosumab: A bone antiresorptive drug. *Med J Armed Forces India.* 2015;71(1):71-75.
68. Dahlan S. Menggunakan rumus besar sampel secara benar. In: *Besar Sampel Dan Cara Pengambilan Sampel.* 3rd ed. Jakarta: Salemba Medika; 2013:35-72.
69. Sastroasmoro S, Ismael S. Perkiraan besar sampel. In: *Dasar Dasar Metodologi Penelitian Klinis.* 3rd ed. Jakarta: Sagung Seto; 2008:302-332.
70. Samara S, Dailiana Z, Chassanidis C, et al. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis. *Exp Mol Pathol.* 2014;96(1):9-14.
71. Artono, Purnami N, Rahmawati R. Biofilm bacteria plays a role in CSOM pathogenesis and has significant correlation with unsafe type CSOM. *Folia Medica Indones.* 2014;51(4):208-213.
72. Asroel HA, Siregar DR, Aboet A. Profil penderita otitis media suppuratif kronis. *J Kesehat Masy Nas.* 2013;7(12):567-571.
73. Yousuf M, Majumder KA, Kamal A, Shumon AM. Clinical study on chronic suppurative otitis media with cholesteatoma. *Bangladesh J Otorhinolaryngol.* 2011;17(1):42-47.
74. Yarisman L, Asroel HA, Aboet A, Zaluchu F. Hubungan ekspresi RANKL dengan derajat destruksi tulang akibat kolesteatoma pada otitis media

supuratif kronik. *ORLI*. 2017;47(1):1-10.

75. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor κ B ligand: clinical utility in metabolic bone disease assessment. *J Clin Endocrinol Metab*. 2005;90(11):6323-6331.
76. Loftis AD, Reeves WK. Principles of Real-Time PCR. *Vet PCR Diagnostics*. 2012:3-17. doi:10.2174/97816080534831120101

